Which has higher valuation and earnings, FOCL or SIBN?

SiBone has higher revenue and earnings than FocalTherics. SiBone is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FocalTherics $70.53M 2.89 -$29.25M -$0.81 N/A SiBone $200.93M 3.94 -$18.90M -$0.39 N/A

Is FOCL or SIBN more profitable?

SiBone has a net margin of -8.10% compared to FocalTherics' net margin of -41.47%. SiBone's return on equity of -9.56% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -41.47% -137.61% -40.62% SiBone -8.10% -9.56% -7.06%

Is FOCL or BBNX more profitable?

FocalTherics has a net margin of -41.47% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -41.47% -137.61% -40.62% Beta Bionics -60.27% -23.00% -20.55%

Is FOCL or CBLL more profitable?

FocalTherics has a net margin of -41.47% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -41.47% -137.61% -40.62% CeriBell -63.51% -38.19% -30.92%

FocalTherics (FOCL) Competitors

$5.43 0.00 (0.00%)

As of 04:00 PM Eastern

Compare

FOCL vs. SIBN, BBNX, CBLL, SSII, and TCMD

Should you buy FocalTherics stock or one of its competitors? MarketBeat compares FocalTherics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FocalTherics include SiBone (SIBN), Beta Bionics (BBNX), CeriBell (CBLL), SS Innovations International (SSII), and Tactile Systems Technology (TCMD). These companies are all part of the "medical equipment" industry.

How does FocalTherics compare to SiBone?

FocalTherics (NASDAQ:FOCL) and SiBone (NASDAQ:SIBN) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

FocalTherics has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

FocalTherics currently has a consensus price target of $6.00, indicating a potential upside of 10.50%. SiBone has a consensus price target of $23.00, indicating a potential upside of 28.85%. Given SiBone's stronger consensus rating and higher possible upside, analysts plainly believe SiBone is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, SiBone had 3 more articles in the media than FocalTherics. MarketBeat recorded 4 mentions for SiBone and 1 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.89 beat SiBone's score of 0.18 indicating that FocalTherics is being referred to more favorably in the media.

Company	Overall Sentiment
FocalTherics	Very Positive
SiBone	Neutral

SiBone has higher revenue and earnings than FocalTherics. SiBone is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.89	-$29.25M	-$0.81	N/A
SiBone	$200.93M	3.94	-$18.90M	-$0.39	N/A

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Comparatively, 3.9% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SiBone has a net margin of -8.10% compared to FocalTherics' net margin of -41.47%. SiBone's return on equity of -9.56% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-41.47%	-137.61%	-40.62%
SiBone	-8.10%	-9.56%	-7.06%

Summary

SiBone beats FocalTherics on 13 of the 15 factors compared between the two stocks.

How does FocalTherics compare to Beta Bionics?

FocalTherics (NASDAQ:FOCL) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

FocalTherics has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.89	-$29.25M	-$0.81	N/A
Beta Bionics	$100.25M	7.53	-$73.20M	-$1.51	N/A

In the previous week, Beta Bionics had 1 more articles in the media than FocalTherics. MarketBeat recorded 2 mentions for Beta Bionics and 1 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.89 beat Beta Bionics' score of 1.64 indicating that FocalTherics is being referred to more favorably in the media.

Company	Overall Sentiment
FocalTherics	Very Positive
Beta Bionics	Very Positive

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

FocalTherics presently has a consensus target price of $6.00, indicating a potential upside of 10.50%. Beta Bionics has a consensus target price of $20.10, indicating a potential upside of 18.58%. Given Beta Bionics' stronger consensus rating and higher probable upside, analysts plainly believe Beta Bionics is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

FocalTherics has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market.

FocalTherics has a net margin of -41.47% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-41.47%	-137.61%	-40.62%
Beta Bionics	-60.27%	-23.00%	-20.55%

Summary

Beta Bionics beats FocalTherics on 10 of the 16 factors compared between the two stocks.

How does FocalTherics compare to CeriBell?

FocalTherics (NASDAQ:FOCL) and CeriBell (NASDAQ:CBLL) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

FocalTherics has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.89	-$29.25M	-$0.81	N/A
CeriBell	$89.06M	8.32	-$53.41M	-$1.63	N/A

FocalTherics presently has a consensus target price of $6.00, suggesting a potential upside of 10.50%. CeriBell has a consensus target price of $22.20, suggesting a potential upside of 13.73%. Given CeriBell's stronger consensus rating and higher probable upside, analysts plainly believe CeriBell is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, CeriBell had 4 more articles in the media than FocalTherics. MarketBeat recorded 5 mentions for CeriBell and 1 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.89 beat CeriBell's score of 0.72 indicating that FocalTherics is being referred to more favorably in the media.

Company	Overall Sentiment
FocalTherics	Very Positive
CeriBell	Positive

FocalTherics has a net margin of -41.47% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-41.47%	-137.61%	-40.62%
CeriBell	-63.51%	-38.19%	-30.92%

62.7% of FocalTherics shares are held by institutional investors. 10.1% of FocalTherics shares are held by company insiders. Comparatively, 20.1% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

FocalTherics has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Summary

CeriBell beats FocalTherics on 11 of the 16 factors compared between the two stocks.

How does FocalTherics compare to SS Innovations International?

FocalTherics (NASDAQ:FOCL) and SS Innovations International (NASDAQ:SSII) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

SS Innovations International has lower revenue, but higher earnings than FocalTherics. SS Innovations International is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.89	-$29.25M	-$0.81	N/A
SS Innovations International	$42.49M	17.14	-$12.13M	-$0.05	N/A

FocalTherics currently has a consensus target price of $6.00, indicating a potential upside of 10.50%. SS Innovations International has a consensus target price of $7.00, indicating a potential upside of 92.31%. Given SS Innovations International's higher probable upside, analysts clearly believe SS Innovations International is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

FocalTherics has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.96, suggesting that its stock price is 296% less volatile than the broader market.

62.7% of FocalTherics shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

SS Innovations International has a net margin of -20.69% compared to FocalTherics' net margin of -41.47%. SS Innovations International's return on equity of -23.00% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-41.47%	-137.61%	-40.62%
SS Innovations International	-20.69%	-23.00%	-13.18%

In the previous week, SS Innovations International had 8 more articles in the media than FocalTherics. MarketBeat recorded 9 mentions for SS Innovations International and 1 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.89 beat SS Innovations International's score of 0.58 indicating that FocalTherics is being referred to more favorably in the media.

Company	Overall Sentiment
FocalTherics	Very Positive
SS Innovations International	Positive

Summary

SS Innovations International beats FocalTherics on 8 of the 15 factors compared between the two stocks.

How does FocalTherics compare to Tactile Systems Technology?

Tactile Systems Technology (NASDAQ:TCMD) and FocalTherics (NASDAQ:FOCL) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Tactile Systems Technology presently has a consensus target price of $38.60, indicating a potential upside of 32.92%. FocalTherics has a consensus target price of $6.00, indicating a potential upside of 10.50%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, analysts plainly believe Tactile Systems Technology is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
FocalTherics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tactile Systems Technology has higher revenue and earnings than FocalTherics. FocalTherics is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tactile Systems Technology	$329.52M	1.99	$19.09M	$0.88	33.00
FocalTherics	$70.53M	2.89	-$29.25M	-$0.81	N/A

In the previous week, Tactile Systems Technology had 1 more articles in the media than FocalTherics. MarketBeat recorded 2 mentions for Tactile Systems Technology and 1 mentions for FocalTherics. FocalTherics' average media sentiment score of 1.89 beat Tactile Systems Technology's score of 0.93 indicating that FocalTherics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tactile Systems Technology	Positive
FocalTherics	Very Positive

83.4% of Tactile Systems Technology shares are owned by institutional investors. Comparatively, 62.7% of FocalTherics shares are owned by institutional investors. 2.1% of Tactile Systems Technology shares are owned by insiders. Comparatively, 10.1% of FocalTherics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tactile Systems Technology has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, FocalTherics has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

Tactile Systems Technology has a net margin of 5.91% compared to FocalTherics' net margin of -41.47%. Tactile Systems Technology's return on equity of 9.70% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tactile Systems Technology	5.91%	9.70%	7.53%
FocalTherics	-41.47%	-137.61%	-40.62%

Summary

Tactile Systems Technology beats FocalTherics on 13 of the 16 factors compared between the two stocks.

Get FocalTherics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FOCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FOCL vs. The Competition

Export

Metric	FocalTherics	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$203.71M	$3.23B	$4.35B	$12.42B
Dividend Yield	N/A	N/A	27.48%	8.01%
P/E Ratio	N/A	22.32	23.77	24.29
Price / Sales	2.89	26.79	103.39	95.49
Price / Cash	N/A	9.27	31.98	49.39
Price / Book	10.44	6.04	12.23	6.29
Net Income	-$29.25M	$23.43M	$118.20M	$330.86M
7 Day Performance	3.23%	-3.67%	-2.64%	-2.41%
1 Month Performance	15.04%	-2.78%	-1.90%	-0.64%
1 Year Performance	N/A	-21.72%	9.16%	20.09%

FocalTherics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FOCL FocalTherics	2.2679 of 5 stars	$5.43 flat	$6.00 +10.5%	N/A	$203.71M	$70.53M	N/A	230
SIBN SiBone	2.6608 of 5 stars	$17.39 -1.6%	$23.00 +32.3%	+2.1%	$771.25M	$200.93M	N/A	350
BBNX Beta Bionics	2.43 of 5 stars	$17.01 +1.8%	$19.70 +15.8%	+34.4%	$758.14M	$100.25M	N/A	294	Analyst Forecast
CBLL CeriBell	1.9288 of 5 stars	$19.95 +0.8%	$22.20 +11.3%	+21.3%	$757.28M	$89.06M	N/A	N/A	Positive News
SSII SS Innovations International	2.2932 of 5 stars	$3.65 -2.2%	$7.00 +91.8%	-24.0%	$730.27M	$42.49M	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FOCL) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FocalTherics (FOCL) Competitors

FOCL vs. SIBN, BBNX, CBLL, SSII, and TCMD

How does FocalTherics compare to SiBone?

Summary

How does FocalTherics compare to Beta Bionics?

Summary

How does FocalTherics compare to CeriBell?

Summary

How does FocalTherics compare to SS Innovations International?

Summary

How does FocalTherics compare to Tactile Systems Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FocalTherics (FOCL) Competitors

FOCL vs. SIBN, BBNX, CBLL, SSII, and TCMD

How does FocalTherics compare to SiBone?

Which has more volatility & risk, FOCL or SIBN?

Do analysts recommend FOCL or SIBN?

Does the media refer more to FOCL or SIBN?

Which has higher valuation and earnings, FOCL or SIBN?

Do institutionals & insiders believe in FOCL or SIBN?

Is FOCL or SIBN more profitable?

Summary

How does FocalTherics compare to Beta Bionics?

Which has better earnings & valuation, FOCL or BBNX?

Does the media favor FOCL or BBNX?

Do institutionals & insiders believe in FOCL or BBNX?

Do analysts recommend FOCL or BBNX?

Which has more risk and volatility, FOCL or BBNX?

Is FOCL or BBNX more profitable?

Summary

How does FocalTherics compare to CeriBell?

Which has higher earnings and valuation, FOCL or CBLL?

Do analysts prefer FOCL or CBLL?

Does the media prefer FOCL or CBLL?

Is FOCL or CBLL more profitable?

Do institutionals & insiders have more ownership in FOCL or CBLL?

Which has more risk & volatility, FOCL or CBLL?

Summary

How does FocalTherics compare to SS Innovations International?

Which has higher valuation & earnings, FOCL or SSII?

Do analysts recommend FOCL or SSII?

Which has more volatility and risk, FOCL or SSII?

Do insiders & institutionals believe in FOCL or SSII?

Is FOCL or SSII more profitable?

Does the media prefer FOCL or SSII?

Summary

How does FocalTherics compare to Tactile Systems Technology?

Do analysts prefer TCMD or FOCL?

Which has preferable valuation and earnings, TCMD or FOCL?

Does the media prefer TCMD or FOCL?

Do institutionals & insiders believe in TCMD or FOCL?

Which has more volatility and risk, TCMD or FOCL?

Is TCMD or FOCL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOCL vs. The Competition

FocalTherics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools